This study is a regulatory post-marketing surveillance in Japan, and it is a local
prospective and observational study of patients who have received Regorafenib for colorectal
cancer.
The objective of this study is to assess safety and effectiveness of Regorafenib using in
real clinical practice.
A total of 1,250 patients are to be enrolled and assessed in 6 months standard observational
period. At 12 months after the first administration of Regorafenib for confirmation of
efficacy information including treatment duration and survival status of the patient.